GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Walvax Biotechnology Co Ltd (SZSE:300142) » Definitions » Shares Outstanding (EOP)

Walvax Biotechnology Co (SZSE:300142) Shares Outstanding (EOP) : 1,607 Mil (As of Mar. 2024)


View and export this data going back to 2011. Start your Free Trial

What is Walvax Biotechnology Co Shares Outstanding (EOP)?

Shares outstanding are shares that have been authorized, issued, and purchased by investors and are held by them. Walvax Biotechnology Co's shares outstanding for the quarter that ended in Mar. 2024 was 1,607 Mil.

Walvax Biotechnology Co's quarterly shares outstanding stayed the same from Dec. 2023 (1,607 Mil) to Mar. 2024 (1,607 Mil).

Walvax Biotechnology Co's annual shares outstanding increased from Dec. 2022 (1,607 Mil) to Dec. 2023 (1,607 Mil). It means Walvax Biotechnology Co issued new shares from Dec. 2022 to Dec. 2023 .


Walvax Biotechnology Co Shares Outstanding (EOP) Historical Data

The historical data trend for Walvax Biotechnology Co's Shares Outstanding (EOP) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Walvax Biotechnology Co Shares Outstanding (EOP) Chart

Walvax Biotechnology Co Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Shares Outstanding (EOP)
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1,537.44 1,546.24 1,601.34 1,607.24 1,607.35

Walvax Biotechnology Co Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Shares Outstanding (EOP) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1,607.35 1,607.35 1,607.35 1,607.35 1,607.35

Competitive Comparison of Walvax Biotechnology Co's Shares Outstanding (EOP)

For the Drug Manufacturers - Specialty & Generic subindustry, Walvax Biotechnology Co's Shares Outstanding (EOP), along with its competitors' market caps and Shares Outstanding (EOP) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Walvax Biotechnology Co's Shares Outstanding (EOP) Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Walvax Biotechnology Co's Shares Outstanding (EOP) distribution charts can be found below:

* The bar in red indicates where Walvax Biotechnology Co's Shares Outstanding (EOP) falls into.



Walvax Biotechnology Co Shares Outstanding (EOP) Calculation

Shares outstanding are shares that have been authorized, issued, and purchased by investors and are held by them. They have voting rights and represent ownership in the corporation by the person that holds the shares. They should be distinguished from treasury shares, which are shares held by the corporation itself, having no exercisable rights.

Shares outstanding can be calculated as either basic or fully diluted. The fully diluted shares outstanding count includes diluting securities, such as options, warrants or convertibles.

Please note: GuruFocus named Shares Outstanding (EOP) is the shares for that end of period. It is usually used to calculate balance sheet related items, such as Book Value per Share, etc. While Shares Outstanding (Diluted Average) and Shares Outstanding (Basic Average) are the weighted average shares over a period of time (a year, a quarter, or so). They are usually used to calculate income statement or cashflow statement related items, such as Earnings per Share (Diluted), etc.


Walvax Biotechnology Co  (SZSE:300142) Shares Outstanding (EOP) Explanation

A company may buy back shares or issue shares in any fiscal period. If a company buys back shares, we should observe that the total number of shares decline. If the company issues new shares, the number of shares outstanding increases.

Usually the presence of treasury shares and a history of buyback are good indicators that company has competitive advantage. But studies have shown that companies usually buy back at wrong time. Buying back shares below its intrinsic value increases value for remaining shareholders. Buying back overvalued shares destroys value for existing shareholders.


Be Aware

Warren Buffett looks for consistency and upward long term trend. Because of share repurchase it is possible for net earnings trend to differ from EPS trend. He preferred net income over EPS. The companies with durable competitive advantage companies report higher % net earnings to total revenues.

Important: If a company is showing net earnings history greater than 20% on total revenues, it is probably benefiting from a long term competitive advantage.

If net earnings is less than 10%, likely to be in a highly competitive business.


Walvax Biotechnology Co Shares Outstanding (EOP) Related Terms

Thank you for viewing the detailed overview of Walvax Biotechnology Co's Shares Outstanding (EOP) provided by GuruFocus.com. Please click on the following links to see related term pages.


Walvax Biotechnology Co (SZSE:300142) Business Description

Traded in Other Exchanges
N/A
Address
Keyuan Road No. 99, 19th Floor, Building 9A, Dingyi Tiancheng Residential Quarter, High & New Tech Development Zone, Yunnan Province, Kunming, CHN, 650106
Walvax Biotechnology Co Ltd biological pharmaceutical enterprise engaged in research and development, production and sales of bio-medicine products. It offers bio-medicines, such as vaccines, blood products, and others. The company's products include Haemophilus influenza type b conjugate vaccines, freeze-dried group A, C meningococcal polysaccharide conjugate vaccines, group ACYW135 meningococcal polysaccharide vaccines, and group A and C meningococcal polysaccharide vaccines.
Executives
Wu Yun Yan Executives
Zhao Jin Long Executives
Yao Wei Executives
Zhou Hua Executives
Shi Jing Executives
Jiang Run Sheng Directors, executives
Gong Sun Qing Executives
Executives
Yuan Lin Executives
Fang Guo Liang Executives
Li Yun Chun Director
Huang Zhen Director
Zhang Li Secretary Dong
Yang Hong Wei Supervisors
Xu Ke Ren Executives

Walvax Biotechnology Co (SZSE:300142) Headlines

No Headlines